Murine leukemia virus (MLV)-based coronavirus spike-pseudotyped particle production and infection - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Bio-protocol Année : 2016

Murine leukemia virus (MLV)-based coronavirus spike-pseudotyped particle production and infection

Résumé

Viral pseudotyped particles (pp) are enveloped virus particles, typically derived from retroviruses or rhabdoviruses, that harbor heterologous envelope glycoproteins on their surface and a genome lacking essential genes. These synthetic viral particles are safer surrogates of native viruses and acquire the tropism and host entry pathway characteristics governed by the heterologous envelope glycoprotein used. They have proven to be very useful tools used in research with many applications, such as enabling the study of entry pathways of enveloped viruses and to generate effective gene-delivery vectors. The basis for their generation lies in the capacity of some viruses, such as murine leukemia virus (MLV), to incorporate envelope glycoproteins of other viruses into a pseudotyped virus particle. These can be engineered to contain reporter genes such as luciferase, enabling quantification of virus entry events upon pseudotyped particle infection with susceptible cells. Here, we detail a protocol enabling generation of MLV-based pseudotyped particles, using the Middle East respiratory syndrome coronavirus (MERS-CoV) spike (S) as an example of a heterologous envelope glycoprotein to be incorporated. We also describe how these particles are used to infect susceptible cells and to perform a quantitative infectivity readout by a luciferase assay.

Dates et versions

hal-02635110 , version 1 (27-05-2020)

Identifiants

Citer

Jean Millet, Gary Whittaker. Murine leukemia virus (MLV)-based coronavirus spike-pseudotyped particle production and infection. Bio-protocol , 2016, 6 (23), ⟨10.21769/BioProtoc.2035⟩. ⟨hal-02635110⟩

Collections

INRAE
30 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More